Press releases & publications.
News about BioGenomics, and the research we publish.
Our insulin aspart mix is approved in India.
In September 2025, our insulin aspart mix, a pre-mixed insulin analogue, was approved in India. It follows our insulin aspart, which patients in India have used since October 2023 under the brand name InsuQuick™. Launch of insulin aspart mix in India is planned.
USV partners with BioGenomics to launch InsuQuick™.
Our insulin aspart has been used by patients in India since October 2023 under the brand name InsuQuick™. The launch was covered by the publications below.
Diabetes drug-maker USV marks entry into insulin with biosimilar of Insulin Aspart
Read article
USV Partners With Biogenomics To Launch INSUQUICK, The First Biosimilar Insulin Aspart for People with Diabetes In India
Read article
USV, Biogenomics launch INSUQUICK, biosimilar Insulin Aspart for diabetes treatment
Read article
USV partners with Biogenomics to launch biosimilar insulin aspart for diabetes in India
Read article
USV Partners With Biogenomics To Launch INSUQUICK, The First Biosimilar Insulin Aspart for People with Diabetes In India
Read article
USV partners with Biogenomics to launch first biosimilar Insulin Aspart for diabetics In India
Read article
USV Launches INSUQUICK, First Biosimilar Insulin Aspart in India
Read article
Our research, peer reviewed.
Our peer-reviewed papers on insulin aspart, from laboratory characterisation to clinical studies.
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart
Dongre SA, Kulkarni GA, Thapa D, Ghade N, Lona J, Prajapati H, et al. Clinical Pharmacology in Drug Development. 2025;14(3):209–216.
Read the paper
Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study
Dongre SA, Kulkarni GA, Mishra A, Deshmane RB, Sonar N, Yashi K, et al. Research in Pharmaceutical Sciences. 2024;19(5):489–499.
Read the paper
Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus
Mishra A, Dongre S, Kulkarni G, Deshmane R, Thappa D, Ghade N, et al. Journal of Endocrinological Investigation. 2024;47(6):1435–1446.
Read the paper
Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL‑ASP and reference insulin aspart
Ghade NS, Thappa DK, Lona J, Krishnan AR, Sonar SM. Scientific Reports. 2024;14:4224.
Read the paper
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart
Mishra AG, Deshmane RB, Thappa DK, Lona J, Ghade NS, Sonar SM, et al. BioDrugs. 2023;37(5):709–719.
Read the paper
Conference posters
Presented at the IDF World Diabetes Congress 2025 in Bangkok (7–10 April 2025). Select a poster to open it.
Biological assays: key to successful development of insulin biosimilar for clinical application
Mishra A, Dongre S, Kulkarni G, Deshmane R, Thappa D, Ghade N, et al.
Comparative bioassay of biphasic insulin aspart mix 30 of BioGenomics with NovoMix® 30 of Novo Nordisk
Deshmane R, Mishra A, Thappa D, Lona J, Ghade N, Kokatam S, et al.